Australia - English - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - paliperidone, quantity: 9 mg - tablet, modified release - excipient ingredients: sodium chloride; iron oxide red; purified water; hyetellose; macrogol 3350; carnauba wax; butylated hydroxytoluene; polyethylene oxide; povidone; stearic acid; isopropyl alcohol; propylene glycol; iron oxide black; hypromellose; titanium dioxide; macrogol 400; cellulose acetate - invega is indicated for the treatment of schizophrenia, including acute treatment and recurrence prevention. invega is indicated for the treatment of acute exacerbations of schizoaffective disorder as monotherapy and in combination with antidepressants and/or mood stabilizers (lithium and valproate).

Australia - English - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - paliperidone, quantity: 6 mg - tablet, modified release - excipient ingredients: butylated hydroxytoluene; sodium chloride; povidone; stearic acid; polyethylene oxide; iron oxide red; hyetellose; macrogol 3350; macrogol 400; carnauba wax; isopropyl alcohol; propylene glycol; cellulose acetate; titanium dioxide; hypromellose; purified water; iron oxide black; iron oxide yellow - invega is indicated for the treatment of schizophrenia, including acute treatment and recurrence prevention. invega is indicated for the treatment of acute exacerbations of schizoaffective disorder as monotherapy and in combination with antidepressants and/or mood stabilizers (lithium and valproate).

Australia - English - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - paliperidone, quantity: 3 mg - tablet, modified release - excipient ingredients: polyethylene oxide; iron oxide yellow; iron oxide red; butylated hydroxytoluene; purified water; carnauba wax; sodium chloride; hypromellose; iron oxide black; lactose monohydrate; triacetin; stearic acid; povidone; macrogol 3350; titanium dioxide; hyetellose; isopropyl alcohol; cellulose acetate; propylene glycol - invega is indicated for the treatment of schizophrenia, including acute treatment and recurrence prevention. invega is indicated for the treatment of acute exacerbations of schizoaffective disorder as monotherapy and in combination with antidepressants and/or mood stabilizers (lithium and valproate).

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

ethypharm uk ltd - pramipexole dihydrochloride monohydrate - modified-release tablet - 1.05mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

ethypharm uk ltd - pramipexole dihydrochloride monohydrate - modified-release tablet - 260microgram

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

ethypharm uk ltd - pramipexole dihydrochloride monohydrate - modified-release tablet - 520microgram

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

ethypharm uk ltd - pramipexole dihydrochloride monohydrate - modified-release tablet - 1.57mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

ethypharm uk ltd - pramipexole dihydrochloride monohydrate - modified-release tablet - 2.1mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

ethypharm uk ltd - pramipexole dihydrochloride monohydrate - modified-release tablet - 2.62mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

ethypharm uk ltd - pramipexole dihydrochloride monohydrate - modified-release tablet - 3.15mg